A Once-Daily Combination Tablet (Atripla) for HIV
Atripla (Gilead/Bristol-Myers Squibb) is the first once daily, single-tablet combination of 3 antiretroviral drugs for treatment of HIV infection. Each tablet contains 600 mg of the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz (Sustiva), 200 mg of the nucleoside reverse transcriptase inhibitor (NRTI) emtricitabine (Emtriva), and 300 mg of the nucleotide reverse transcriptase inhibitor (NRTI) tenofovir DF (Viread). These drugs have been recommended for use together, if resistance testing confirms susceptibility, as an initial regimen of choice for treatment-na∩ve patients....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: A Once-Daily Combination Tablet (Atripla) for HIV
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1244
Article Code: 1244b
Date: September 25, 2006
Volume: 48
Pages: 78-79
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1244
Article Code: 1244b
Date: September 25, 2006
Volume: 48
Pages: 78-79
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)